PICTET ASSET MANAGEMENT SA 13D and 13G filings for Neoleukin Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2023-02-03 11:56 am Sale |
2022-12-31 | 13G | Neoleukin Therapeutics, Inc. NLTX |
PICTET ASSET MANAGEMENT SA | 0 0.000% |
-128,714 (Position Closed) |
Filing |
| 2022-02-10 11:10 am Purchase |
2022-02-10 | 13G | Neoleukin Therapeutics, Inc. NLTX |
PICTET ASSET MANAGEMENT SA | 128,714 6.070% |
128,714 (New Position) |
Filing |